Inebilizumab
- Product Name
- Inebilizumab
- CAS No.
- 1299440-37-1
- Chemical Name
- Inebilizumab
- Synonyms
- Inebilizumab;Inebilizumab (anti-CD19);Research Grade Inebilizumab;Research Grade Inebilizumab(DHD10802);MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551
- CBNumber
- CB18080940
- Formula Weight
- 0
- MOL File
- Mol file
Inebilizumab Property
- form
- Liquid
- color
- Colorless to light yellow
N-Bromosuccinimide Price
- Product number
- orb1290196
- Product name
- Inebilizumab
- Purity
- >95%
- Packaging
- 100μg
- Price
- $240
- Updated
- 2026/05/06
- Product number
- orb1290196
- Product name
- Inebilizumab
- Purity
- >95%
- Packaging
- 1mg
- Price
- $820
- Updated
- 2026/05/06
- Product number
- SLK-A2564
- Product name
- Inebilizumab (Anti-CD19)
- Packaging
- 1mg
- Price
- $257
- Updated
- 2026/05/26
- Product number
- HY-P99113
- Product name
- Inebilizumab
- Purity
- 99.00%
- Packaging
- 1mg
- Price
- $228
- Updated
- 2026/05/26
- Product number
- HY-P99113
- Product name
- Inebilizumab
- Purity
- 99.00%
- Packaging
- 5mg
- Price
- $589
- Updated
- 2026/05/26
Inebilizumab Chemical Properties,Usage,Production
Uses
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].
in vivo
Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2].
| Animal Model: | huCD19/CD20 double Tg mice[2] |
| Dosage: | 0.5, 2, or 10 mg/kg |
| Administration: | Tail vein injection, once |
| Result: | Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages. |
References
[1] Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5(12):107. DOI:10.3390/jcm5120107
[2] Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. DOI:10.1124/jpet.110.168062
Inebilizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Inebilizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 89686
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32466
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310 15002144251
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24955
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9865
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7081
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11972
- Advantage
- 58
- Tel
- 6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 49998
- Advantage
- 58